Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Savara Inc.

    NASDAQ: SVRA · Real-Time Price · USD
    2.06
    -0.12 (-5.50%)
    At close: Jun 17, 2025, 3:59 PM
    2.00
    -2.68%
    After-hours: Jun 17, 2025, 04:38 PM EDT
    -5.50%
    Bid 2
    Market Cap 355.18M
    Revenue (ttm) 272K
    Net Income (ttm) -102.17M
    EPS (ttm) -0.49
    PE Ratio (ttm) -4.19
    Forward PE -4.5
    Analyst Buy
    Ask 2.15
    Volume 645,704
    Avg. Volume (20D) 1,486,298
    Open 2.18
    Previous Close 2.18
    Day's Range 2.04 - 2.20
    52-Week Range 1.89 - 5.11
    Beta 0.32

    About SVRA

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol SVRA
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for SVRA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    2 weeks ago
    +9.79%
    Savara shares are trading higher. Guggenheim maint... Unlock content with Pro Subscription
    3 weeks ago
    -31.69%
    Savara shares are trading lower after the company announced it received a refusal to file letter from the FDA for its biologics license application.
    news image

    1 day ago · accessnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

    NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Savara Inc.("Savara" or the "Company") (NASDAQ:SVRA). Such investors are advised t...

    news image

    2 weeks ago · accessnewswire.com

    Did Savara Inc. (SVRA) Mislead Investors? Levi & Korsinsky Investigates

    NEW YORK, NY / ACCESS Newswire / May 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Savara Inc. ("Savara Inc.") (NASDAQ:SVRA) concerning possible violations o...

    news image

    2 weeks ago · accessnewswire.com

    SVRA ALERT: Levi & Korsinsky Investigates Savara Inc. on Behalf of Shareholders Who Lost Money

    NEW YORK, NY / ACCESS Newswire / May 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Savara Inc. ("Savara Inc.") (NASDAQ:SVRA) concerning possible violations o...

    news image

    2 weeks ago · accessnewswire.com

    Levi & Korsinsky Launches Fraud Investigation on Behalf of Savara Inc. (SVRA) Shareholders

    NEW YORK, NY / ACCESS Newswire / May 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Savara Inc. ("Savara Inc.") (NASDAQ:SVRA) concerning possible violations o...

    news image

    2 weeks ago · accessnewswire.com

    Savara Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation

    BOSTON, MA / ACCESS Newswire / May 28, 2025 / Block & Leviton is investigating Savara Inc. (Nasdaq:SVRA) for potential securities law violations. Investors who have lost money in their Savara Inc. inv...

    news image

    3 weeks ago · benzinga.com

    Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday?

    Savara Inc. SVRA on Tuesday announced that it received a U.S. Food And Drug Administration (FDA) refusal To File (RTF)) letter regarding the Biologic license application (BLA) for Molbreevi, a therapy...

    news image

    3 weeks ago · businesswire.com

    Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP)

    LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company received an...

    news image

    3 weeks ago · businesswire.com

    Savara Announces New Employment Inducement Grant

    LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new...

    news image

    3 weeks ago · businesswire.com

    Savara Announces Participation in Jefferies Global Healthcare Conference

    LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management te...

    news image

    1 month ago · businesswire.com

    Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025

    LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced new data in two poster prese...

    Add to Watchlist